Seaport Therapeutics’ (SPTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Seaport Therapeutics (NASDAQ:SPTX) in a research note issued to investors on Thursday,Benzinga reports. They currently have a $50.00 price target on the stock.

SPTX has been the topic of several other reports. Stifel Nicolaus started coverage on shares of Seaport Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $30.00 price target on the stock. Wall Street Zen raised shares of Seaport Therapeutics to a “hold” rating in a research note on Saturday, May 9th. BNP Paribas Exane lowered shares of Seaport Therapeutics to a “market perform” rating in a report on Tuesday, May 26th. Zacks Research upgraded shares of Seaport Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Finally, Leerink Partners started coverage on shares of Seaport Therapeutics in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $35.00 target price on the stock. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $38.40.

Seaport Therapeutics Trading Up 1.2%

SPTX opened at $24.31 on Thursday. The company has a market capitalization of $1.30 billion and a PE ratio of -2.01. Seaport Therapeutics has a 52 week low of $14.85 and a 52 week high of $26.32. The company has a fifty day moving average price of $21.04.

Seaport Therapeutics (NASDAQ:SPTX) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($1.07). As a group, equities research analysts predict that Seaport Therapeutics will post -4.6 EPS for the current year.

Insider Transactions at Seaport Therapeutics

In related news, Director Robert J. Hombach purchased 13,000 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were acquired at an average cost of $18.14 per share, with a total value of $235,820.00. Following the purchase, the director directly owned 13,000 shares of the company’s stock, valued at approximately $235,820. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Institutional Trading of Seaport Therapeutics

Institutional investors have recently made changes to their positions in the stock. Alyeska Investment Group L.P. bought a new position in shares of Seaport Therapeutics in the second quarter worth approximately $1,629,000. Braidwell LP bought a new stake in Seaport Therapeutics during the 2nd quarter valued at $10,860,000. Finally, TRV GP VI LLC bought a new stake in Seaport Therapeutics during the 2nd quarter valued at $44,769,742,000.

Seaport Therapeutics Company Profile

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.